Drug · DIN 02298465
RISPERDAL CONSTA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 24, 2007; first marketed October 24, 2007.
- Drug Identification Number (DIN)
- 02298465
- Company (DIN owner)
- Janssen Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Powder For Suspension (Sustained-Release; Kit
- Route
- Intramuscular
- Therapeutic class (ATC)
- Risperidone N05AX08
- Class
- Human
- Record last updated
- June 23, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RISPERIDONE | 12.5 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 14, 2007: NOC 8973Supplement to a New Drug Submission (SNDS) · New strength: 12.5 mg/vial and other related revisions to the product monograph
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “risperdal”. A notice may cover another product or only some lots: read it to see what it covers.
Other DINs named RISPERDAL CONSTA
- DIN 02255707 · Marketed
- DIN 02255723 · Marketed
- DIN 02255758 · Marketed